To support our data, it has been previously published that increased expression of Slit2 was present in other malignant tumors, including malignant melanoma, mucinous adenocarcinoma of the rectum, invasive carcinoma of breast, squamous carcinoma of stomach, hepatocellular carcinoma, and metastatic CRC [6, 7]. Here, SLIT2 is linked to hepatocellular carcinoma.